Article Text

Download PDFPDF
Designer Natriuretic Peptides
  1. Candace Y. W. Lee, MD, PhD*,
  2. Hsiao Lieu, MD, PhD,
  3. John C. Burnett Jr, MD*
  1. From the *Cardiorenal Research Laboratory, Division of Cardiovascular Disease, Departments of Internal Medicine and Physiology, Mayo Clinic College of Medicine, Rochester, MN; and †Nile Therapeutics, San Francisco, CA.
  1. Received November 3, 2008.
  2. Accepted for publication November 5, 2008.
  3. Reprints: John C. Burnett, Jr, MD, Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55906 (e-mail: burnett.john{at}
  4. This study was supported by the National Institutes of Health (R01 HL36634, P01 HL76611, and R01 HL83231) and the Mayo Foundation (grants to J.C.B.), the Canadian Institutes of Health Research Clinical Research Initiative Fellowship Award (2006-07), a 2007 Heart Failure Society of America Research Fellowship Award, and the 2007 American Society for Clinical Pharmacology and Therapeutics Young Investigator Award to C.Y.W.L.


Designer natriuretic peptides (NPs) are novel hybrid peptides that are engineered from the native NPs through addition, deletion, or substitution of amino acid(s) with a goal toward optimization of pharmacological actions while minimizing undesirable effects. In this article, selected peptides that were designed in our laboratory are reviewed, and future directions for research and development of designer NPs are discussed.

Key Words
  • natriuretic peptide
  • renal function
  • hybrid peptides
View Full Text

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.